LQFM030 reduced Ehrlich ascites tumor cell proliferation and VEGF levels

Mota, Mariana Flávia da; Carvalho, Flávio Silva de; Ávila, Renato Ivan de; Ávila, Paulo Henrique Marcelino de; Cortez, Alane Pereira; Menegatti, Ricardo; Sabino, José R.; Santos, Thaís Rosa Marques dos; Gomes, Sandro Antônio; Cunha, Luíz Carlos da; Valadares, Marize Campos

doi:10.1016/j.lfs.2017.12.029

Cited by 6 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, although known to significantly reduce ascites volume, none of these agents improved OS in clinical trials 36 . Regarding MDM2 inhibitors, previous studies reported that LQFM030 shows antitumor effects and an inhibitory effect on ascites production on Ehrlich ascites tumor cells derived from breast cancer 37,38 . Although the genetic and biological characteristics of CCCs are becoming clear, no single specific inhibitor has been shown to be sufficiently effective.…”

Section: Discussionmentioning

confidence: 99%

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Ehrlich tumor cells develop ascetically when the cells are injected intraperitoneally (Fernandes et al, 2015) or solidly when the cells are injected subcutaneously or in the footpad (Bahr et al, 2015). This tumor corresponds to an aggressive carcinoma with fast growth, which induces myelosuppression and affects the inflammatory response (Brozovic et al, 2009), being a good experimental model for studying the interaction of different substances and the immune system in the tumor development (da Mota et al, 2018;Machado et al, 2017;Moura et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Effects of Ouabain in Ehrlich Tumor Development in vitro and in vivo

Salmeron¹,

Calado

Antunes

et al. 2023

BIOMEDNATPROCH

View full text Add to dashboard Cite

Ouabain (OUA) is a cardiotonic steroid with an immunomodulatory and anti-inflammatory role in different experimental models. Currently, the potential antineoplastic effect of OUA has been studied, however, research is needed to better understand OUA role during tumor development. Therefore, our aim was to investigate the OUA effects on Ehrlich tumor (ET) development in vitro and in vivo. To evaluate the cytotoxic effects of OUA on ET in vitro the cells were incubated with different concentrations of OUA during 24h and 48h and our results showed that only the [1000 ?M] decreased the number and viability of ET cells in the two analyzed times. To study the OUA effects on ET in vivo, Swiss mice were pretreated with 0.56 mg/kg of OUA intraperitoneally (i.p.) for three consecutive days. To develop ET in the solid form, one hour after the last day of pretreatment, ET cells were inoculated subcutaneously into the footpad and the animals were monitored for 13 days. To develop the ascitic form, ET cells were inoculated (i.p.) and the animals were monitored for 3 days. OUA was able to reduce the thickness and weight of the tumor paw, in addition to reduce the weight of the popliteal lymph node. In the ascitic tumor, OUA reduced the number of neutrophils and macrophages and increased the lymphocytes in the peritoneum. Thus, we demonstrated that OUA affects ET development both in vitro and in vivo. Our results suggest a new perspective in the anti-inflammatory, immunomodulatory and a possible anti-cancer role of ouabain and brings new concepts about the pathophysiological role of this substance.

show abstract